RS55764B1 - Inhibitori histonskih demetilaza - Google Patents
Inhibitori histonskih demetilazaInfo
- Publication number
- RS55764B1 RS55764B1 RS20170216A RSP20170216A RS55764B1 RS 55764 B1 RS55764 B1 RS 55764B1 RS 20170216 A RS20170216 A RS 20170216A RS P20170216 A RSP20170216 A RS P20170216A RS 55764 B1 RS55764 B1 RS 55764B1
- Authority
- RS
- Serbia
- Prior art keywords
- methyl
- ethyl
- pyridine
- compound
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708806P | 2012-10-02 | 2012-10-02 | |
| DKPA201200599 | 2012-10-02 | ||
| US201361770050P | 2013-02-27 | 2013-02-27 | |
| DKPA201370112 | 2013-02-27 | ||
| PCT/EP2013/070457 WO2014053491A1 (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
| EP13770928.3A EP2903968B1 (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55764B1 true RS55764B1 (sr) | 2017-07-31 |
Family
ID=52781382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170216A RS55764B1 (sr) | 2012-10-02 | 2013-10-01 | Inhibitori histonskih demetilaza |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20150203453A1 (https=) |
| EP (3) | EP3023415B1 (https=) |
| JP (2) | JP6530313B2 (https=) |
| KR (1) | KR102160320B1 (https=) |
| CN (2) | CN104981458B (https=) |
| AP (1) | AP2015008389A0 (https=) |
| AU (1) | AU2018200876C1 (https=) |
| BR (1) | BR112015007083A2 (https=) |
| CA (2) | CA3095019C (https=) |
| CL (1) | CL2015000829A1 (https=) |
| CR (1) | CR20150217A (https=) |
| CY (1) | CY1118695T1 (https=) |
| DK (1) | DK2903968T3 (https=) |
| EA (1) | EA030698B1 (https=) |
| ES (2) | ES2654143T3 (https=) |
| HK (1) | HK1215710A1 (https=) |
| HR (1) | HRP20170358T1 (https=) |
| HU (1) | HUE033380T2 (https=) |
| IL (2) | IL237831A (https=) |
| LT (1) | LT2903968T (https=) |
| MD (1) | MD20150043A2 (https=) |
| ME (1) | ME02597B (https=) |
| MX (1) | MX2015003959A (https=) |
| NZ (1) | NZ706635A (https=) |
| PE (1) | PE20150998A1 (https=) |
| PH (2) | PH12015500730A1 (https=) |
| PL (2) | PL2903968T3 (https=) |
| PT (2) | PT2903968T (https=) |
| RS (1) | RS55764B1 (https=) |
| SG (2) | SG11201502452RA (https=) |
| SI (2) | SI2903968T1 (https=) |
| SM (2) | SMT201700109T1 (https=) |
| WO (1) | WO2014053491A1 (https=) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| PE20151667A1 (es) | 2013-02-27 | 2015-11-27 | Epitherapeutics Aps | Inhibidores de histona desmetilasas |
| CA2943824A1 (en) * | 2014-03-31 | 2015-10-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2910226T3 (es) | 2014-09-17 | 2022-05-12 | Celgene Quanticel Res Inc | Inhibidores de desmetilasa de histonas |
| EP3194387B1 (en) | 2014-09-17 | 2019-07-31 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| RU2684396C2 (ru) | 2014-10-29 | 2019-04-09 | Донг-А Ст Ко., Лтд. | Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS) |
| TWI716367B (zh) * | 2014-10-31 | 2021-01-21 | 麻省理工學院 | 用於常間回文重複序列叢集（ｃｒｉｓｐｒ）之大量平行組合性基因學 |
| US20160303095A1 (en) * | 2015-04-14 | 2016-10-20 | Gilead Sciences, Inc. | Methods of treating hepatitis b virus |
| US10206930B2 (en) * | 2015-08-14 | 2019-02-19 | New York University | Methods for treating T-cell acute lymphoblastic leukemia |
| US11998540B2 (en) * | 2015-12-11 | 2024-06-04 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
| WO2017117154A1 (en) * | 2015-12-28 | 2017-07-06 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3430008B1 (en) * | 2016-03-15 | 2022-05-18 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017198785A1 (en) * | 2016-05-18 | 2017-11-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Oxime derivatives useful as inhibitors of histone demethylase kdm4c |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| CN108464984A (zh) * | 2018-04-09 | 2018-08-31 | 徐州维康生物科技有限公司 | 一种治疗骨肉瘤的表观遗传药物 |
| CN108186643B (zh) * | 2018-04-09 | 2021-04-20 | 徐州维康生物科技有限公司 | 一种具有协同抗骨肉瘤功效的药物组合物及其应用 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CN108530381B (zh) * | 2018-05-07 | 2021-09-21 | 上海科技大学 | 一种由酰胺酯制备二胺衍生物的方法 |
| JP2021530444A (ja) | 2018-06-28 | 2021-11-11 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| AU2019318046B2 (en) * | 2018-08-06 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Histone demethylase 5 inhibitors and uses thereof |
| CN109234313A (zh) * | 2018-09-25 | 2019-01-18 | 上海交通大学医学院附属第九人民医院 | 共转染载体及其在抗骨肉瘤药物中的应用 |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| CN110652589A (zh) * | 2019-10-12 | 2020-01-07 | 中国人民解放军陆军军医大学 | Gasc1抑制剂在制备治疗肝癌的药物中的应用 |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| CN111073900B (zh) * | 2019-12-09 | 2023-05-02 | 温氏食品集团股份有限公司 | 一种提高猪克隆胚胎发育效率的方法 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021241658A1 (ja) | 2020-05-26 | 2021-12-02 | 株式会社ヘリオス | 低免疫原性細胞 |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CN111905102A (zh) * | 2020-09-04 | 2020-11-10 | 福建医科大学附属第一医院 | Ezh2抑制剂在治疗胶质瘤中的应用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN114907317B (zh) * | 2022-06-01 | 2023-06-13 | 郑州大学 | 一种吡唑-乙烯基-异烟酸衍生物及其制备方法和应用 |
| CN115806522B (zh) * | 2022-11-24 | 2025-05-13 | 中国药科大学 | 一种取代吡啶衍生物及其应用 |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| GB8717374D0 (en) * | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
| AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
| US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
| ES2312695T3 (es) | 1996-11-18 | 2009-03-01 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epotilones e y f. |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| CA2322157C (en) | 1998-02-25 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| KR20070027584A (ko) * | 2004-06-17 | 2007-03-09 | 와이어쓰 | 고나도트로핀 방출 호르몬 수용체 길항제 |
| CA2658362A1 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| WO2009119088A1 (ja) * | 2008-03-25 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
| SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
| RU2011121655A (ru) * | 2008-10-29 | 2012-12-10 | Сертрис Фармасьютикалз, Инк. | Производные пиридина, бициклические производные пиридина и родственные аналоги в качестве модуляторов сиртуина |
| EP2461835A4 (en) | 2009-08-07 | 2013-05-15 | Wistar Inst | COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| JP5841529B2 (ja) * | 2010-05-27 | 2016-01-13 | あすか製薬株式会社 | 複素環化合物及びｈ１受容体拮抗剤 |
| WO2012007008A1 (en) * | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibitors of hdme |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| SI2744330T1 (sl) | 2011-08-15 | 2020-11-30 | University Of Utah Research Foundation | Substituirani (E)-N'-(1-feniletiliden) benzohidrazidni analogi kot inhibitorji histon-demetilaze |
| KR101941048B1 (ko) * | 2011-10-27 | 2019-01-22 | 아스텔라스세이야쿠 가부시키가이샤 | 아미노 알킬 치환 n-티에닐벤즈아미드 유도체 |
| JP6164556B2 (ja) * | 2011-12-01 | 2017-07-19 | 国立大学法人 千葉大学 | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 |
| CN102585150B (zh) * | 2012-02-01 | 2013-09-04 | 嘉兴学院 | 织物涂饰用阴离子水性聚氨酯分散体的制备方法 |
| WO2013123411A1 (en) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| WO2013129435A1 (ja) * | 2012-02-28 | 2013-09-06 | 協和発酵キリン株式会社 | 縮環チオフェン誘導体 |
| DK2903968T3 (en) | 2012-10-02 | 2017-01-30 | Gilead Sciences Inc | INHIBITORS OF HISTON DEMETHYLASES |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| SMT201800070T1 (it) | 2012-12-19 | 2018-03-08 | Celgene Quanticel Res Inc | Inibiorti di istone demetilasi |
| BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
| PE20151667A1 (es) | 2013-02-27 | 2015-11-27 | Epitherapeutics Aps | Inhibidores de histona desmetilasas |
| CA2903465A1 (en) | 2013-03-15 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EP3041474B1 (en) | 2013-09-05 | 2020-03-18 | Genentech, Inc. | Antiproliferative compounds |
| CA2943824A1 (en) | 2014-03-31 | 2015-10-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
-
2013
- 2013-10-01 DK DK13770928.3T patent/DK2903968T3/en active
- 2013-10-01 ES ES15200672.2T patent/ES2654143T3/es active Active
- 2013-10-01 NZ NZ706635A patent/NZ706635A/en not_active IP Right Cessation
- 2013-10-01 JP JP2015534985A patent/JP6530313B2/ja active Active
- 2013-10-01 CA CA3095019A patent/CA3095019C/en active Active
- 2013-10-01 SI SI201330511A patent/SI2903968T1/sl unknown
- 2013-10-01 MX MX2015003959A patent/MX2015003959A/es unknown
- 2013-10-01 PL PL13770928T patent/PL2903968T3/pl unknown
- 2013-10-01 CN CN201380059974.0A patent/CN104981458B/zh active Active
- 2013-10-01 MD MDA20150043A patent/MD20150043A2/ro not_active Application Discontinuation
- 2013-10-01 US US14/381,558 patent/US20150203453A1/en active Granted
- 2013-10-01 PT PT137709283T patent/PT2903968T/pt unknown
- 2013-10-01 SI SI201330878T patent/SI3023415T1/en unknown
- 2013-10-01 PT PT152006722T patent/PT3023415T/pt unknown
- 2013-10-01 LT LTEP13770928.3T patent/LT2903968T/lt unknown
- 2013-10-01 RS RS20170216A patent/RS55764B1/sr unknown
- 2013-10-01 KR KR1020157011211A patent/KR102160320B1/ko active Active
- 2013-10-01 ME MEP-2017-46A patent/ME02597B/me unknown
- 2013-10-01 CA CA2885969A patent/CA2885969C/en active Active
- 2013-10-01 EP EP15200672.2A patent/EP3023415B1/en active Active
- 2013-10-01 EA EA201500394A patent/EA030698B1/ru not_active IP Right Cessation
- 2013-10-01 HK HK16103714.1A patent/HK1215710A1/zh unknown
- 2013-10-01 HR HRP20170358TT patent/HRP20170358T1/hr unknown
- 2013-10-01 BR BR112015007083A patent/BR112015007083A2/pt active Search and Examination
- 2013-10-01 EP EP13770928.3A patent/EP2903968B1/en active Active
- 2013-10-01 SG SG11201502452RA patent/SG11201502452RA/en unknown
- 2013-10-01 ES ES13770928.3T patent/ES2617905T3/es active Active
- 2013-10-01 SM SM20170109T patent/SMT201700109T1/it unknown
- 2013-10-01 WO PCT/EP2013/070457 patent/WO2014053491A1/en not_active Ceased
- 2013-10-01 SG SG10201703682YA patent/SG10201703682YA/en unknown
- 2013-10-01 CN CN201710513194.9A patent/CN107434803B/zh active Active
- 2013-10-01 AP AP2015008389A patent/AP2015008389A0/xx unknown
- 2013-10-01 EP EP16186022.6A patent/EP3150582A1/en not_active Withdrawn
- 2013-10-01 PL PL15200672T patent/PL3023415T3/pl unknown
- 2013-10-01 PE PE2015000454A patent/PE20150998A1/es not_active Application Discontinuation
- 2013-10-01 HU HUE13770928A patent/HUE033380T2/en unknown
-
2014
- 2014-08-28 US US14/472,059 patent/US10189787B2/en active Active
-
2015
- 2015-03-19 IL IL237831A patent/IL237831A/en not_active IP Right Cessation
- 2015-04-01 CL CL2015000829A patent/CL2015000829A1/es unknown
- 2015-04-01 PH PH12015500730A patent/PH12015500730A1/en unknown
- 2015-04-28 CR CR20150217A patent/CR20150217A/es unknown
-
2017
- 2017-02-16 SM SM201700109T patent/SMT201700109B/it unknown
- 2017-02-17 US US15/436,055 patent/US10221139B2/en active Active
- 2017-03-07 CY CY20171100297T patent/CY1118695T1/el unknown
- 2017-07-02 IL IL253259A patent/IL253259B/en not_active IP Right Cessation
- 2017-07-19 PH PH12017501306A patent/PH12017501306A1/en unknown
- 2017-11-07 JP JP2017214526A patent/JP2018016661A/ja active Pending
-
2018
- 2018-02-06 AU AU2018200876A patent/AU2018200876C1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS55764B1 (sr) | Inhibitori histonskih demetilaza | |
| AU2014222756B2 (en) | Inhibitors of histone demethylases | |
| AU2015306662A1 (en) | Compounds and methods for inhibiting histone demethylases | |
| AU2018200982A1 (en) | Inhibitors of histone demethylases | |
| Class et al. | Patent application title: INHIBITORS OF HISTONE DEMETHYLASES | |
| HK1235404A1 (en) | Inhibitors of histone demethylases | |
| HK1223612B (en) | Inhibitors of histone demethylases | |
| HK1207373B (en) | Inhibitors of histone demethylases | |
| HK1247920B (zh) | 组蛋白去甲基化酶抑制剂 | |
| HK1247920A1 (zh) | 组蛋白去甲基化酶抑制剂 | |
| HK1236522A1 (en) | Ethyl pyridine-4-carboxylate compound as inhibitor of histone demethylases |